Peter Nixon, MD
Ophthalmology · Austin, TXNPI 1467438531
Payments from drug & device makers
Across 56 payments — averaging $70.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- AbbVie$517
- Genentech USA, Inc.$276
- Regeneron Healthcare Solutions, Inc.$268
- Astellas Pharma US Inc$248
- Carl Zeiss Meditec, Inc.$176
- plus $927 from 13 others
What the payments were for
- Grants$50013%
- Travel & lodging$1053%
- Food & beverage$1,63241%
- Gifts$1764%
- Ownership interest$1,56039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 10 | $1,560 |
| AbbVie | 2 | $517 |
| Genentech USA, Inc. | 8 | $276 |
| Regeneron Healthcare Solutions, Inc. | 4 | $268 |
| Astellas Pharma US Inc | 12 | $248 |
| Carl Zeiss Meditec, Inc. | 1 | $176 |
| Alimera Sciences, Inc. | 3 | $175 |
| Genentech, Inc. | 1 | $150 |
| Alcon | 2 | $142 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $122 |
| Pfizer | 1 | $105 |
| Novartis | 3 | $61 |
| ANI Pharmaceuticals, Inc. | 2 | $51 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Neurotech Pharmaceuticals, Inc. | 1 | $26 |
| Dutch Ophthalmic, USA | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$500
- CLARUS$176
- VABYSMO$150
- Iluvien$127
- Lucentis$125
- Tecnis Simplicity$122
- Tecnis IOL$122
- EYLEA$122
- Constellation$118
- PREVNAR 20$105
How this compares
$3,972 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 31 | $5,592 |
| Prednisolone Acetate | 105 | $3,186 |
| Ketorolac Tromethamine | 83 | $1,350 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 80 | $781 |
| Timolol Maleate | 32 | $213 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Austin
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Philip StoreyAustin$2.1M
- Saradha ChexalAustin$1.8M
- James DoonerAustin$556K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.